Pitt Team Finds Protein That Ramps Up Inflammation, and Agents That Can Block It
Could Improve Treatments for Pneumonia and Other Inflammatory Conditions
PITTSBURGH, April 1, 2013
– Scientists at the University of Pittsburgh School of Medicine
discovered a new biological pathway of innate immunity that ramps up inflammation and then identified agents that can block it, leading to increased survival and improved lung function in animal models of pneumonia. They reported their findings today in Nature Immunology
Pneumonia and other infections sometimes provoke an inflammatory response from the body that is more detrimental than the disease-causing bacteria, said senior author Rama Mallampalli, M.D
, professor and vice chair for research, Department of Medicine, and director of the Acute Lung Injury Center of Excellence
“In our ongoing studies of pneumonia, we found infecting bacteria activate a previously unknown protein called Fbxo3 to form a complex that degrades another protein called Fbxl2, which is needed to suppress the inflammatory response,” said Dr. Mallampalli, who is also chief of the pulmonary division of the VA Pittsburgh Healthcare System
. “The result is an exaggerated inflammatory response that can lead to further damage of the lung tissue, multi-organ failure and shock.”
Research team members Bryan J. McVerry, M.D
., and Yingze Zhang, Ph.D
., both of the Acute Lung Injury Center of Excellence, found that blood samples from 16 people who had sepsis, a condition of systemic inflammation, revealed higher levels of Fbxo3 –- along with other inflammatory proteins -- and lower levels of Fbxl2 than samples from seven patients who did not have sepsis or lung infection.
Based on the structure of Fbxo3, the researchers developed a family of small molecules with the aim of inhibiting its activity. Administration of one of them, called BC-1215, led to reduced inflammatory markers and improved lung mechanics in mouse models of pneumonia and sepsis.
“The key is to find ways to help the body temper its inflammatory response so that it’s able to kill the infectious agent without causing injury to healthy tissue,” Dr. Mallampalli said.
“The F-box protein Fbxo3, and other related proteins, represent ideal targets for treatment of acute lung injury, because it controls the innate immune response, is upstream of important inflammatory signaling pathways, and is more selective than traditional drugs that regulate protein turnover,” noted Mark T. Gladwin, M.D
., the PACCM chief.
The team is beginning to study the effects of BC-1215 on other conditions of systemic inflammation, such as colitis and arthritis.
Co-authors of the paper include Tiffany A. Coon, Jennifer R. Glasser, Jing Zhao, Ph.D., Yutong Zhao, M.D, Ph.D., Chunbin Zou, Ph.D, Bryon Ellis, and Frank C. Sciurba, M.D., all of the Acute Lung Injury Center of Excellence, University of Pittsburgh.